Tradestie Institutional Equity Comparison Engine

NUVB vs ZYME โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZYME Overall Edge

ZYME Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zymeworks Inc. (ZYME) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, NUVB trades at N/M Forward P/E with -61.2% operating margin (+242.6% YoY revenue) versus ZYME at 55.0x Forward P/E and 22.6% operating margin (+828.7% YoY). In options structure, NUVB sits in BREAKDOWN (26th %ile IV; Dealer Gamma Walls on Pro) against ZYME sits in CONSOLIDATION (45th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner ZYME
NUVB N/M vs ZYME 55.0x Fwd P/E
Growth & Margin Winner ZYME
Op Margin -61.2% vs 22.6% ยท YoY +242.6% vs +828.7%
Momentum & Technical Winner ZYME
1Y -46.9% vs +15.7% ยท 52W Pos 2% vs 44%
Options & Structure Winner ZYME
BREAKDOWN (26th %ile IV) vs CONSOLIDATION (45th %ile IV)
NUVB NYSE
Nuvation Bio Inc.
Pharmaceutical Preparations
$3.80
-0.26% 1D
Market Cap $1.3B
1M Return -19.15%
1Y Return -46.85%
Forward P/E N/M
Unified AI Score
61.0 / 100 BUY
Tech 53.0 Fund 61.0 Flow 67.0 Mom 64.0
ZYME NASDAQ
Zymeworks Inc.
Pharmaceutical Preparations
$26.14
-2.68% 1D
Market Cap $1.9B
1M Return -8.09%
1Y Return +15.66%
Forward P/E 55.0x
Unified AI Score
59.5 / 100 HOLD
Tech 60.0 Fund 59.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NUVB -46.85% ZYME +15.66% Spread: +62.51 pp (ZYME Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period NUVB Revenue ZYME Revenue NUVB Op. Margin ZYME Op. Margin Margin Edge
FY2020 N/A $40M N/A -481.3% ZYME
FY2021 N/A $30M N/A -808.2% ZYME
FY2022 N/A $410M N/A 31.6% ZYME
FY2023 N/A $80M N/A -181.6% ZYME
FY2024 $10M $80M -7527.3% -179.7% ZYME
FY2025 $60M $110M -338.7% -87.3% ZYME

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NUVB (2) vs ZYME (8)
Institutional Metric NUVB ZYME Criterion Row Winner
Market Capitalization Scale $1.3B $1.9B Larger Scale ZYME
Trailing P/E Ratio Valuation N/M 50.7x Lower Multiple ZYME
Forward P/E Ratio Valuation N/M 55.0x Lower Multiple ZYME
Revenue Growth (YoY) Growth +242.6% +828.7% Higher Growth ZYME
Operating Margin (TTM) Profitability -61.2% 22.6% Higher Margin ZYME
Net Profit Margin Profitability -67.4% 16.3% Higher Margin ZYME
Return on Equity (ROE) Capital Efficiency -49.1% 15.0% Higher ROE ZYME
52-Week Range Position Momentum 2% ($4โ€“$10) 44% ($22โ€“$32) Stronger Trend ZYME
Beta / 30D Volatility Risk Regime 1.52ฮฒ ยท 55% Vol 0.87ฮฒ ยท 56% Vol Lower Realized Risk NUVB
Unified Institutional Score Composite Signal 61.0 / 100 (BUY) 59.5 / 100 (HOLD) Higher Composite NUVB

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NUVB vs ZYME Buy Guide
NUVB BREAKDOWN
105d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 26th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live NUVB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZYME CONSOLIDATION
56d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 45th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ZYME Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NUVB nor ZYME registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.